Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Celldex Interim Data Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Sarah Cavanaugh, Senior Vice President of Corporate Affairs. Thank you. Please go ahead, ma'am.
Thank you. Good morning, and thank you all for joining us to discuss the exciting interim data set we reported earlier today from our Phase IB study of CDX-0159 in chronic inducible urticaria. With me on the call today from Celldex are Anthony Marucci, Co-Founder, President and CEO; Dr. Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs and Medical Lead on the study; Dr. Diane Young, Senior Vice President and Chief Medical Officer; Dr. Tibor Keler, Co-Founder, Executive Vice President and Chief Scientific Officer; and Dr. Diego Alvarado, Senior Director of Research and the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |